Robert Phillips

Principal in Charge – Hong Kong

I partner with life science and technology companies to help them grow and succeed, by guiding them through the process of accessing capital markets, raising funds, achieving strategic transactions and complying with corporate governance and securities laws.

+1 415 693 2020

Rob Phillips has extensive experience advising public and private companies on general corporate issues, including corporate finance, securities laws compliance, corporate governance, debt exchanges and complex restructurings and M&A. He also advises US and non-US issuers and investment banks in capital markets offerings, including initial public offerings, follow-ons, convertible debt and high yield debt offerings. In addition to being a corporate partner, Rob is a registered foreign lawyer in Cooley HK, a registered foreign law firm in Hong Kong, which practices in association with CYL & Partners, a firm of Hong Kong solicitors, which includes Will Cai and Pang Lee, who are also partners in Cooley LLP. He is also a member of the Cooley San Francisco office.

Download full bio


  • Vaxcyte - $288 Milion IPO 

  • Legend Biotech - $487 Million IPO 

  • Eiger BioPharmaceuticals: $49 Million Follow-On 

  • 89bio – $98 Million IPO 

  • Oportun Financial – $108 Million IPO  

  • View all


  • Georgetown University Law Center
    JD, 1999

  • Georgetown University
    BSFS, cum laude, 1994

Admissions & Credentials



+1 415 693 2020 office

CYL & Partners
in Association with Cooley HK

Suites 3501 – 3505, 35/F
Two Exchange Square
8 Connaught Place
Central, Hong Kong  

Other Offices